Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.

The reason Novo Nordisk is losing patent protection is because it wouldn't pay a couple hundred bucks. In 2019, the Canadian patent office sent a letter saying it hadn't received Novo Nordisk's annual ...